drug resistant tuberculosis: gold, glitter and hope

Facing extensively drug-resistant tuberculosis--a hope and a challenge.

As of June 2008, a total of 49 countries worldwide reported to the World Health Organization (WHO) at least one case of extensively drug-resistant tuberculosis. Since its first description in March 2006,1 this disease has become the most alarming issue in international tuberculosis control and one that seriously risks compromising the progress observed in many countries over the past decade.2 E...

Tuberculosis drug development pipeline: progress and hope.

multidrug-resistant and extensively drug-resistant tuberculosis

multidrug-resistant (mdr) and extensively drug-resistant (xdr) tuberculosis (tb) are increasing globally. treatment options for these patients are very limited. although treatment of these patients with standardized regimen is associated with high mortality and morbidity, rational usage of new drugs might be promising. in this study we will review epidemiology of xdr-tb and tdr-tb in iran and t...

Multidrug-resistant and extensively drug-resistant tuberculosis.

Tuberculosis (TB) can usually be treated with a course of four standard, or first-line, anti-TB drugs. If these are misused or mismanaged (that is, when drugs are taken in the wrong combination, are fewer than those prescribed, or are taken in insufficient doses or not at the proper time), multidrugresistant TB (MDR-TB) can develop. MDR-TB is a form of disease resistant to the most important an...

Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis.

The continuing spread of drug-resistant tuberculosis (TB) is one of the most urgent and difficult challenges facing global TB control. Patients who are infected with strains resistant to isoniazid and rifampicin, called multidrug-resistant (MDR) TB, are practically incurable by standard first-line treatment. In 2012, there were approximately 450,000 new cases and 170,000 deaths because of MDR-T...

Extensively drug-resistant tuberculosis.

Extensively drug-resistant (XDR) tuberculosis is defined as disease caused by Mycobacterium tuberculosis with resistance to at least isoniazid and rifampicin, any fluoroquinolone, and at least one of three injectable second-line drugs (amikacin, capreomycin, or kanamycin). The definition has applicable clinical value and has allowed for more uniform surveillance in varied international settings...